SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities l

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering le

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of

SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BBNX--Johnson Fistel, PLLP is investigating potential securiti

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slowe

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit

San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating poten

SAN DIEGO, June 5, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities l

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigatin

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bion

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in

SAN DIEGO--(BUSINESS WIRE)---- $bbnx #BBNX--Johnson Fistel, PLLP is investigating whether Beta Bioni

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigatin

Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes manage

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the

Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes manage

B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lo

Leerink Partners analyst Mike Kratky maintains Beta Bionics (NASDAQ:BBNX) with a Outperform and l

Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric

Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $130.000 million-$135.000 million to $13

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.49) per share which met the analyst cons

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the

Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the pri

Beta Bionics (NASDAQ:BBNX) sees FY2026 sales of $130.000 million-$135.000 million vs $132.717 millio

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.30) per share which beat the analyst con

Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lo

On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "

TD Cowen analyst Mathew Blackman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Hold rat

Beta Bionics reported Q4 2025 sales growth, but analysts raised concerns about valuation and slower

Lake Street analyst Frank Takkinen maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the